Chemical Nameberotralstat
Dosage FormCapsules (oral; 150mg, 110mg)
Drug ClassInhibitors
CompanyBioCryst Pharmaceuticals, Inc.
Approval Year2020


  • For prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Orladeyo (berotralstat) Prescribing Information. 2020BioCryst Pharmaceuticals, Inc. Durham, NC